---
search:
  boost: 2 
---

# Hepatitis C

This is a subcategory of Infectious Disease Agents.

## Formulary

### Preferred

| Preferred                              | Generic Name | Quantity | Time (Days) |
| :------------------------------------- | :----------- | :------: | :---------: |
| Mavyret <sup>PA</sup>                  |              |          |             |
| Pegasys <sup>PA</sup>                  |              |          |             |
| Ribavirin <sup>PA</sup>                |              |          |             |
| Sofosbuvir / Velpatasvir <sup>PA</sup> |              |          |             |

### Non-Preferred

| Non-Preferred           | Generic Name | Quantity | Time (Days) |
| :---------------------- | :----------- | :------: | :---------: |
| Harvoni                 |              |          |             |
| Ledipasvir / Sofosbuvir |              |          |             |
| Sovaldi                 |              |          |             |
| Vosevi                  |              |          |             |
| Zepatier                |              |          |             |

## Authorizations

**Length of Authorizations**: Dependent upon authorized course

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Clinical PA

Clinical PA Criteria

- Only regimens recommended by the American Association for the Study of Liver Diseases (AASLD) will be authorized
- Please see the [Hepatitis C Direct Acting Antiviral Prior Authorization Form](https://pharmacy.medicaid.ohio.gov/sites/default/files/HepC_PA_Form_20211119.pdf#overlay-context=prior-authorization) for criteria 

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response defined as not achieving SVR with guideline-recommended preferred drugs
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Additional Information

- Requests for patients established on current therapy with prior payer (i.e., Commercial, Fee-for-Service, Managed Care Plan, etc) will be authorized with documentation
- Requests for regimens including pegylated Interferons must include close monitoring with periodic clinical and laboratory evaluations
- Requests for regimens including ribavirins must include documentation of at least two reliable forms of contraception being used during therapy

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL%20_Criteria_APPROVED.pdf#page=81)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL_APPROVED_12.13.22.pdf#page=27)

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf)
